| Dr Edward W Yeh, MD | |
|
2720 Sunset Blvd, West Columbia, SC 29169-4810 | |
| (803) 791-2000 | |
| Not Available |
| Full Name | Dr Edward W Yeh |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 29 Years |
| Location | 2720 Sunset Blvd, West Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184709941 | NPI | - | NPPES |
| T42022 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 20098 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lexington Medical Center | West columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lexington Health Inc | 2567872070 | 753 |
News Archive
A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.
Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.
The European-American Chamber of Commerce will host a conference on Health & Wellness in Cincinnati to explore the challenges and opportunities organizations face as health care policies undergo dramatic changes locally, nationally and abroad.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments. Toxic side-effects can occur months or years after the treatments are finished, sometimes as chronic conditions, sometimes life-threatening, but always unacceptably reducing a patient's quality of life.
› Verified 9 days ago
| Entity Name | Lexington Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710634753 PECOS PAC ID: 2567872070 Enrollment ID: O20201208000922 |
News Archive
A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.
Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.
The European-American Chamber of Commerce will host a conference on Health & Wellness in Cincinnati to explore the challenges and opportunities organizations face as health care policies undergo dramatic changes locally, nationally and abroad.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments. Toxic side-effects can occur months or years after the treatments are finished, sometimes as chronic conditions, sometimes life-threatening, but always unacceptably reducing a patient's quality of life.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward W Yeh, MD Po Box 6069, West Columbia, SC 29171-6069 Ph: () - | Dr Edward W Yeh, MD 2720 Sunset Blvd, West Columbia, SC 29169-4810 Ph: (803) 791-2000 |
News Archive
A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.
Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.
The European-American Chamber of Commerce will host a conference on Health & Wellness in Cincinnati to explore the challenges and opportunities organizations face as health care policies undergo dramatic changes locally, nationally and abroad.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
The cure rates for many cancers have improved dramatically over the past decades, but the harsh reality is that too many cancer survivors suffer serious side-effects of their curative treatments. Toxic side-effects can occur months or years after the treatments are finished, sometimes as chronic conditions, sometimes life-threatening, but always unacceptably reducing a patient's quality of life.
› Verified 9 days ago
Dr. Stephen A Grant, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Dr. Wesley H Shuler, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Dr. Stephen J Platte, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Dr. Adrian D Langley, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2541 Fax: 803-939-4579 | |
Dr. Jill B Healey, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Dr. Carol Hyun Choe, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2480 Fax: 803-936-4102 | |
David A Kranc, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 |